ArticleJournal of translational medicine2025
Microbial Anti-Inflammatory Molecule (MAM) secreted by Faecalibacterium prausnitzii ameliorates colitis through autophagy and gut microbiota modulation.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Faecalibacterium prausnitzii: Mechanistic Insights and Therapeutic Potential in Host-Microbe Crosstalk.Probiotics and antimicrobial proteins · 2026Review
- Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy.Nature communications · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveFaecalibacterium prausnitzii is a major commensal bacterium that plays a crucial role in intestinal homeostasis. Its secretes an microbial anti-inflammatory molecule (MAM) that functions as a potential therapeutic agent in inflammatory bowel disease (IBD). However, the molecular mechanisms through which MAM exerts its beneficial effects remain incompletely understood. Here, we investigate whether MAM modulates autophagy and to evaluate its therapeutic potential in a murine model of colitis.
methodsA genetically engineered Lactococcus lactis strain expressing MAM was administered to mice with dextran sulfate sodium (DSS)-induced or 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The therapeutic effects of MAM were evaluated using clinical scoring, histopathological analysis, and inflammatory cytokines measurement. Intestinal barrier function was assessed based on tight junction protein expression. Autophagy-related signaling pathways were analyzed using western blotting and immunohistochemistry. To determine how autophagy affects MAM, DSS-treated mice were treated with the autophagy inhibitor hydroxychloroquine (HCQ) and bafilomycin A1 (BafA1). Gut microbiota composition was profiled 16 S rRNA gene amplicon sequencing. Fecal short-chain fatty acid (SCFA) levels were quantified by gas chromatography–mass spectrometry (GC-MS).
resultsMAM treatment significantly alleviated colitis in both DSS- and TNBS-induced models, as evidenced by reduced disease activity, improved colon length, attenuated histopathological damage, and decreased pro-inflammatory cytokine production. MAM enhanced intestinal barrier integrity by upregulating ZO-1 and occludin. Notably, MAM counteracted the inhibitory effect of HCQ/BafA1 on autophagy, enhancing autophagic flux despite autophagy suppression. Furthermore, MAM treatment significantly increased the fecal concentrations of acetate, propionate, and butyrate. 16 S sequencing revealed the enrichment of beneficial taxa, including Lactobacillus and Lachnospiraceae_NK4A136_group, The abundance of these taxa was positively correlated with SCFA levels and improvement of colitis symptoms.
conclusionWe identified MAM as a multifunctional microbial effector with potent anti-inflammatory properties. MAM improves intestinal barrier function and attenuates experimental colitis through dual mechanisms involving the modulation of autophagy and gut microbiota composition. These findings highlight the translational potential of MAM and support further investigation into its use as a novel therapeutic strategy for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.